PMID- 28602029
OWN - NLM
STAT- MEDLINE
DCOM- 20180329
LR  - 20220317
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 6
IP  - 7
DP  - 2017 Jul
TI  - The prognostic impact of programmed cell death ligand 1 and human leukocyte 
      antigen class I in pancreatic cancer.
PG  - 1614-1626
LID - 10.1002/cam4.1087 [doi]
AB  - Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive 
      tumor-microenvironment (TME) that supports the growth of tumors and mediates 
      tumors enabling evasion of the immune system. Expression of programmed cell death 
      ligand 1 (PD-L1) and loss of human leukocyte antigen (HLA) class I on tumor cells 
      are methods by which tumors escape immunosurveillance. We examined immune cell 
      infiltration, the expression of PD-L1 and HLA class I by PDA cells, and the 
      correlation between these immunological factors and clinical prognosis. PDA 
      samples from 36 patients were analyzed for HLA class I, HLA-DR, PD-L1, PD-1, CD4, 
      CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations 
      between the expression of HLA class I, HLA-DR, PD-L1 or PD-1 and the pattern of 
      tumor infiltrating immune cells or the patients' prognosis were assessed. PD-L1 
      expression correlated with tumor infiltration by CD68(+) and FoxP3(+) cells. Low 
      HLA class I expression was an only risk factor for poor survival. PD-L1 negative 
      and HLA class I high-expressing PDA was significantly associated with higher 
      numbers of infiltrating CD8(+) T cells in the TME, and a better prognosis. 
      Evaluation of both PD-L1 and HLA class I expression by PDA may be a good 
      predictor of prognosis for patients. HLA class I expression by tumor cells should 
      be evaluated when selecting PDA patients who may be eligible for treatment with 
      PD-1/PD-L1 immune checkpoint blockade therapies.
CI  - (c) 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Imai, Daisuke
AU  - Imai D
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Yoshizumi, Tomoharu
AU  - Yoshizumi T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Okano, Shinji
AU  - Okano S
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
AD  - Department of General surgery, Digestive Disease and Surgery institute, Cleveland 
      Clinic, Cleveland, USA.
FAU - Uchiyama, Hideaki
AU  - Uchiyama H
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Ikegami, Toru
AU  - Ikegami T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Harimoto, Norifumi
AU  - Harimoto N
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Itoh, Shinji
AU  - Itoh S
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Soejima, Yuji
AU  - Soejima Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Aishima, Shinichi
AU  - Aishima S
AD  - Department of Pathology and Microbiology, Saga Medical School, Faculty of 
      Medicine, Saga University, Saga, Japan.
FAU - Oda, Yoshinao
AU  - Oda Y
AD  - Department of Anatomic Pathology, Pathological sciences, Graduate School of 
      Medical Sciences, Kyushu University, Fukuoka, Japan.
FAU - Maehara, Yoshihiko
AU  - Maehara Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170610
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - B7-H1 Antigen/genetics/*metabolism
MH  - Biomarkers
MH  - Female
MH  - Gene Expression
MH  - Histocompatibility Antigens Class I/genetics/*immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymphocytes, Tumor-Infiltrating/immunology/metabolism
MH  - Macrophages/immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Pancreatic Neoplasms/diagnosis/*immunology/*metabolism/mortality
MH  - Prognosis
MH  - Recurrence
MH  - Survival Analysis
MH  - Tumor Burden
MH  - Tumor Microenvironment/genetics/immunology
PMC - PMC5504334
OTO - NOTNLM
OT  - Biomarker
OT  - human leukocyte antigens class I
OT  - immunotherapy
OT  - pancreatic cancer
OT  - programmed cell death ligand 1
EDAT- 2017/06/12 06:00
MHDA- 2018/03/30 06:00
PMCR- 2017/06/10
CRDT- 2017/06/12 06:00
PHST- 2016/12/28 00:00 [received]
PHST- 2017/04/02 00:00 [revised]
PHST- 2017/04/04 00:00 [accepted]
PHST- 2017/06/12 06:00 [pubmed]
PHST- 2018/03/30 06:00 [medline]
PHST- 2017/06/12 06:00 [entrez]
PHST- 2017/06/10 00:00 [pmc-release]
AID - CAM41087 [pii]
AID - 10.1002/cam4.1087 [doi]
PST - ppublish
SO  - Cancer Med. 2017 Jul;6(7):1614-1626. doi: 10.1002/cam4.1087. Epub 2017 Jun 10.